Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03097315 · ClinicalTrials.gov registry record · Phase 3
Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis
A Phase 3 study, sponsored by Clearside Biomedical.
- Completed
- Registry status
- Phase 3
- Development phase
- 38
- Enrollment target
NCT03097315: Completed Phase 3 study, sponsored by Clearside Biomedical.
NCT03097315 is a Phase 3 study that has completed, run by Clearside Biomedical. The registered enrollment target is 38 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03097315, a Phase 3 study, has completed, sponsored by Clearside Biomedical.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 38 participants
- Enrollment target
Study Summary
This open-label study is designed to evaluate the safety of suprachoroidally administered triamcinolone acetone injectable suspension, CLS-TA, in patients with non-infectious uveitis with and without macular edema.
Primary Outcome
Number of patients with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs). An adverse event (AE) is the development of an undesirable medical condition or the deterioration of a preexisting medical condition after or during exposure to a pharmaceutical product, whether or not considered causally related to the product. A TEAE is an AE occurring on or after the date of the first dose of study drug or worsening relative to the pre-treatment state. An SAE is an AE that ful
Interventions
- DRUG 4 mg CLS-TA Suprachoriodal Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2017-04-04 |
| Est. Completion | 2018-01-24 |
| Phase | Phase 3 |
What the finished NCT03097315 record still lists
NCT03097315 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which 4 mg CLS-TA Suprachoriodal Injection is the first listed.
NCT03097315 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03097315 about?
NCT03097315 is a clinical study titled "Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis". This open-label study is designed to evaluate the safety of suprachoroidally administered triamcinolone acetone injectable suspension, CLS-TA, in patients with non-infectious uveitis with and without macular edema.
What is the current status of trial NCT03097315?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 38 participants. The study started on 2017-04-04. Estimated completion is 2018-01-24.
What interventions are being tested in trial NCT03097315?
The interventions under investigation include: 4 mg CLS-TA Suprachoriodal Injection (DRUG).
Who is sponsoring clinical trial NCT03097315?
This trial is sponsored by Clearside Biomedical, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03097315's enrollment target sits among peer trials
38 1900th of 2000 higher than 100 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI